EBIT: Income before interest and taxes.
Skye Bioscience, Inc. (SKYE) had EBIT of $-14.90M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-14.44M |
|
-- |
|
-- |
|
$14.90M |
|
$-14.90M |
|
$0.45M |
|
$-14.44M |
|
$-14.62M |
|
$-14.44M |
|
$-14.44M |
|
$-14.44M |
|
$-14.62M |
|
|
EBIT |
$-14.90M |
$-14.72M |
|
39.66M |
|
39.66M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$27.09M |
|
$0.90M |
|
$1.22M |
|
$28.31M |
|
$8.21M |
|
-- |
|
$0.08M |
|
$8.29M |
|
$20.02M |
|
$20.02M |
|
$20.02M |
|
33.38M |
|
| Cash Flow Statement Financials | |
$-43.06M |
|
$-19.50M |
|
$0.03M |
|
$68.42M |
|
$5.88M |
|
$-62.53M |
|
$7.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-42.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-72.12% |
|
-72.12% |
|
-51.01% |
|
-72.12% |
|
$0.60 |
|
$-1.08 |
|
$-1.09 |
|